MedTrace Logo

COVID-19 and Psychotic Symptoms in France

NCT04356885 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2020-12-29

No results posted yet for this study

Summary

Study the impact of containment related to COVID-19 pandemic on psychotic experiences in the general population in France.

Conditions

  • Mental Disorder

Sponsors & Collaborators

  • Epsylon Laboratory, EA 4556, University Paul Valéry Montpellier 3, France

    collaborator UNKNOWN

  • Laboratoy LIP/PC2S, University Grenobles-Alpes, Grenoble, France

    collaborator UNKNOWN

  • Centre référent de réhabilitation psychosociale de Grenoble, Grenoble, France

    collaborator UNKNOWN

  • University Hospital, Montpellier

    lead OTHER

Principal Investigators

  • Stéphane Raffard, PhD · University Hospitals of Montpellier

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-04-01
Primary Completion
2020-07-30
Completion
2020-08-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04356885 on ClinicalTrials.gov